Attached files

file filename
EX-32.1 - EX-32.1 - Stoke Therapeutics, Inc.stok-ex321_7.htm
EX-31.2 - EX-31.2 - Stoke Therapeutics, Inc.stok-ex312_9.htm
EX-31.1 - EX-31.1 - Stoke Therapeutics, Inc.stok-ex311_6.htm
10-Q - 10-Q - Stoke Therapeutics, Inc.stok-10q_20200331.htm

 

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Stephen J. Tulipano, Chief Financial Officer of Stoke Therapeutics, Inc. (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.

the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended March 31, 2020  (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: May 15, 2020

 

/s/ Stephen J. Tulipano, CPA

 

 

Stephen J. Tulipano, CPA

 

 

Chief Financial Officer

 

 

(Principal Financial Officer and

 

 

Principal Accounting Officer)